Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
IRCCS Azienda Ospedaliero-Universitaria di Bologna
100 participants
Mar 22, 2024
OBSERVATIONAL
Conditions
Summary
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
Eligibility
Inclusion Criteria3
- Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
- Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
- Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.
Interventions
Data on oncologic drugs administered for treatment of breast cancer will be recorded
Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06800612